CRISPR Gene Therapy Significantly Reduces Hereditary Angioedema Attacks in Trial

A CRISPR-based gene therapy demonstrated significant reduction of hereditary angioedema (HAE) attacks in trial patients, according to MedPage Today. The results mark a new disease indication for CRISPR therapeutics, expanding the therapeutic reach of gene editing beyond sickle cell disease and hemophilia into the rare immunological disorder space. HAE is caused by C1 esterase inhibitor deficiency and can cause life-threatening swelling episodes.